Zelicapavir not checked
Enanta Pharmaceuticals, Inc · EDP-938
FollowEvery change as it happens, and a Monday email
Trials
2 active
11 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- Tested for
- RSV (2 trials), RSV Infection, Respiratory Syncytial Virus (RSV)
- Main trialPhase 2/3
- “Zelicapavir is a novel orally administered non-fusion replication inhibitor of RSV that is being developed for the treatment of patients with RSV infection. This phase 2b/3 study will evaluate the efficacy and safety of zelicapavir compared with placebo in adults with RSV who are at high risk for severe disease. High-risk participants include those who are either ≥75 years of age or ≥18 years of age with COPD and/or CHF. Participants will be non-hospitalized adults who have up to 72 hours of respiratory tract infection symptoms and test positive for RSV.”In the company’s words, NCT07908381 on ClinicalTrials.gov
- Other names
- EDP-938
Other drugs for RSV
- TQC3721Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Phase 3
- EnsifentrineMerck & Co. · Nuance Pharma · Phase 3
- HSK39004Haisco Pharmaceutical Group Co., Ltd. · Phase 3
- AstegolimabRoche · Phase 3
- Alpha-1 MPGrifols Therapeutics LLC · Phase 3
- JKN2401Joincare Pharmaceutical Group Industry Co., Ltd · Phase 3
Coming up2
- DecPhase 2 trial completes · ClinicalTrials.gov
- Jul 2029Phase 2/3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials11
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2/3Recruiting | Jul 2029 | A Study to Investigate the Efficacy and Safety of Zelicapavir Compared With Placebo in Adults With RSV Who Are at High Risk for Severe Disease | |
| Phase 2Recruiting | Dec 2026 | A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus | |
| Phase 2Completed | 30 Sep 2019 | A Phase 2a Study to Evaluate EDP-938 in the Virus Challenge Model | |
| Phase 2Completed | 4 Jan 2022 | A Study to Assess EDP-938 for the Treatment of Acute Upper Respiratory Tract Infection With Respiratory Syncytial Virus in Adult Subjects | |
| Phase 2Terminated | 31 May 2023 | Effects of EDP-938 in Hematopoietic Cell Transplant Recipients Infected With Respiratory Syncytial Virus of the Upper Respiratory Tract | |
| Phase 2Completed | 19 Aug 2024 | A Study to Evaluate EDP 938 Regimens in Children With RSV | |
| Phase 2Completed | 23 Jun 2025 | A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications. | |
| Phase 1Completed | 30 Mar 2021 | Drug-Drug Interaction Study Between Fluconazole and EDP-938 in Healthy Subjects | |
| Phase 1Completed | 27 May 2021 | Drug-Drug Interaction Study Between EDP-938, Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy Subjects | |
| Phase 1Completed | 4 Jul 2021 | Absorption, Metabolism, and Excretion (AME) Study of [14C]EDP-938 in Healthy Male Subjects | |
| Phase 1Completed | 2 Feb 2025 | A Study to Investigate the Effects of Zelicapavir (EDP-938) on QTc Interval in Healthy Adults |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026